KR101287918B1 - 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신 - Google Patents

엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신 Download PDF

Info

Publication number
KR101287918B1
KR101287918B1 KR1020077009355A KR20077009355A KR101287918B1 KR 101287918 B1 KR101287918 B1 KR 101287918B1 KR 1020077009355 A KR1020077009355 A KR 1020077009355A KR 20077009355 A KR20077009355 A KR 20077009355A KR 101287918 B1 KR101287918 B1 KR 101287918B1
Authority
KR
South Korea
Prior art keywords
pld
therapeutically effective
administered
formulated
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077009355A
Other languages
English (en)
Korean (ko)
Other versions
KR20070108135A (ko
Inventor
에라르 길
라르스－아셀 스테르나스
오비드 트리판
데 벨데 헬기 반
에이프릴 테이텔바움
Original Assignee
오르토 바이오테크 프로덕츠 엘.피.
파르마 마르 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101287918(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오르토 바이오테크 프로덕츠 엘.피., 파르마 마르 에스.에이. filed Critical 오르토 바이오테크 프로덕츠 엘.피.
Publication of KR20070108135A publication Critical patent/KR20070108135A/ko
Application granted granted Critical
Publication of KR101287918B1 publication Critical patent/KR101287918B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020077009355A 2004-10-26 2005-10-26 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신 Expired - Lifetime KR101287918B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
US60/622,163 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (2)

Publication Number Publication Date
KR20070108135A KR20070108135A (ko) 2007-11-08
KR101287918B1 true KR101287918B1 (ko) 2013-07-19

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077009355A Expired - Lifetime KR101287918B1 (ko) 2004-10-26 2005-10-26 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신

Country Status (26)

Country Link
US (1) US20090117176A1 (https=)
EP (1) EP1827500B1 (https=)
JP (2) JP4554684B2 (https=)
KR (1) KR101287918B1 (https=)
CN (1) CN101119750B (https=)
AT (1) ATE430586T1 (https=)
AU (1) AU2005298364B2 (https=)
BR (1) BRPI0518250A2 (https=)
CA (1) CA2582452C (https=)
CY (1) CY1110329T1 (https=)
DE (1) DE602005014380D1 (https=)
DK (1) DK1827500T3 (https=)
ES (1) ES2326825T3 (https=)
HR (1) HRP20090345T1 (https=)
IL (1) IL182352A (https=)
MX (1) MX2007004744A (https=)
NO (1) NO328958B1 (https=)
NZ (1) NZ554765A (https=)
PL (1) PL1827500T3 (https=)
PT (1) PT1827500E (https=)
RS (1) RS50822B (https=)
RU (1) RU2359700C2 (https=)
SI (1) SI1827500T1 (https=)
UA (1) UA87877C2 (https=)
WO (1) WO2006046080A2 (https=)
ZA (1) ZA200703396B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1365808B1 (en) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN101489593B (zh) 2006-06-19 2015-11-25 约翰·霍普金斯大学 通过脂质体酶的治疗剂肿瘤特异性递送
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) * 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EE200300429A (et) * 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
WO2004006755A2 (en) * 2002-07-16 2004-01-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743

Also Published As

Publication number Publication date
PL1827500T3 (pl) 2009-09-30
NO20072543L (no) 2007-07-13
JP2009292850A (ja) 2009-12-17
AU2005298364A1 (en) 2006-05-04
ZA200703396B (en) 2008-11-26
MX2007004744A (es) 2007-10-23
US20090117176A1 (en) 2009-05-07
EP1827500B1 (en) 2009-05-06
RS50822B (sr) 2010-08-31
PT1827500E (pt) 2009-08-05
NZ554765A (en) 2010-01-29
WO2006046080A8 (en) 2007-07-12
JP4554684B2 (ja) 2010-09-29
ES2326825T3 (es) 2009-10-20
DE602005014380D1 (de) 2009-06-18
EP1827500A2 (en) 2007-09-05
CN101119750B (zh) 2013-03-06
CA2582452A1 (en) 2006-05-04
HK1107766A1 (en) 2008-04-18
BRPI0518250A2 (pt) 2008-11-11
CY1110329T1 (el) 2015-01-14
WO2006046080A3 (en) 2006-10-19
UA87877C2 (en) 2009-08-25
ATE430586T1 (de) 2009-05-15
NO328958B1 (no) 2010-06-28
WO2006046080A2 (en) 2006-05-04
CN101119750A (zh) 2008-02-06
JP2008517991A (ja) 2008-05-29
IL182352A0 (en) 2007-07-24
KR20070108135A (ko) 2007-11-08
AU2005298364B2 (en) 2009-03-26
SI1827500T1 (sl) 2009-10-31
RU2359700C2 (ru) 2009-06-27
HRP20090345T1 (en) 2009-08-31
DK1827500T3 (da) 2009-08-31
RU2007119545A (ru) 2008-12-10
CA2582452C (en) 2010-09-07
IL182352A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
JP2009292850A (ja) 抗癌治療
US6403563B1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
KR20160023816A (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
CN108348480A (zh) 使用脂质体伊立替康和parp抑制剂用于癌症治疗的组合疗法
BRPI0707059A2 (pt) método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação
US20210267915A1 (en) Use of mitoxantrone liposome for treating non-hodgkin's lymphoma
EP4098251B1 (en) Mitoxantrone hydrochloride liposome for use in treating breast cancer
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
TWI469776B (zh) 有助於癌症之治療的方法，組成物以及製品
EA005311B1 (ru) Препараты эстрамустина фосфата и основных аминокислот для парентерального применения
US20140135357A1 (en) Dose regime for camptothecin derivatives
US20040033271A1 (en) Methods for contemporaneous administration of levamisole and 5-fluorouracil
US7998973B2 (en) Tivozanib and temsirolimus in combination
ES3037120T3 (en) Thiostrepton and vitamin e-tpgs for treating cancer
HK1107766B (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
CA3126211A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
US20040038904A1 (en) Method of treating multiple sclerosis
EP1200099B1 (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
Fountain DRUG PREPARATIONS OF REDUCED TOXCITY 75 Inventors
US20200390702A1 (en) Liposomal taxanes for treatment of sclc
HK40044845A (en) Use of mitoxantrone liposome for treating non-hodgkin’s lymphoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070425

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121016

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130424

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130715

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130716

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160630

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170630

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170630

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210630

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230629

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 13

End annual number: 13